Synthesis and cytotoxic activity of γ-aryl substituted α-alkylidene-γ-lactones and α-alkylidene-γ-lactams
A series of 5-aryl-3-alkylidenedihydrofuran-2(3 H)-ones and 5-aryl-3-methylidenepyrrolidi-2-nones were synthesized starting from 4-aryl-2-diethoxyphosphoryl-4-oxobutanoates. Target compounds were evaluated for their cytotoxic activity against L-1210, HL-60 and NALM-6 cell lines. A series of 5-aryl-3...
Gespeichert in:
Veröffentlicht in: | Bioorganic & medicinal chemistry 2008-05, Vol.16 (9), p.4872-4882 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | A series of 5-aryl-3-alkylidenedihydrofuran-2(3
H)-ones and 5-aryl-3-methylidenepyrrolidi-2-nones were synthesized starting from 4-aryl-2-diethoxyphosphoryl-4-oxobutanoates. Target compounds were evaluated for their cytotoxic activity against L-1210, HL-60 and NALM-6 cell lines.
A series of 5-aryl-3-alkylidenedihydrofuran-2(3
H)-ones
6a–
g″ and
11a,
b as well as 5-aryl-3-methylidenepyrrolidin-2-ones
10a–
c and
12 were synthesized starting from 4-aryl-2-diethoxyphosphoryl-4-oxobutanoates
3a–
g. Reaction sequence includes reduction or reductive amination of the carbonyl group, lactonization or lactamization step and finally the Horner–Wadsworth–Emmons olefination of aldehydes using thus obtained 5-aryl-3-diethoxyphosphoryl-3,4-dihydrofuran-2(5
H)-ones
5a–
g″ or 5-aryl-3-diethoxyphosphorylpyrrolidin-2-ones
9a–
c. Furanones
6 and
11, as well as pyrrolidinones
10 and
12, were evaluated in vitro against mouse leukemia cell line L-1210 and two human leukemia cell lines HL-60 and NALM-6. Several of the obtained furanones proved to be very potent against all three cell lines with IC
50 values lower than 6 μM. Structure–activity relationships of these compounds, as well as 5-alkyl or 5-arylmethyl-3-methylidenedihydrofuran-2(3
H)-ones
13a–
e, previously obtained in our laboratory, are discussed. |
---|---|
ISSN: | 0968-0896 1464-3391 |
DOI: | 10.1016/j.bmc.2008.03.035 |